Anglo-Swedish drugmaker AstraZeneca’s (LSE: AZN) global biologics research and development arm, MedImmune, is to join forces with the University of Michigan and Eli Lilly (NYSE: LLY) to identify new therapeutic targets for the treatment of chronic kidney diseases (CKD), it has been announced.
The renal pre-competitive consortium (RPC2) will combine the R&D expertise of the pharmaceutical industry with clinical and molecular data collected by University of Michigan nephrologist, Matthias Kretzler.
Professor Kretzler has established a renal database containing information from more than 1,000 patients, as well as from multiple animal models of CKD to advance research into the condition.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze